Epic Sciences平台循环肿瘤细胞计数作为转移性去势抵抗性前列腺癌预后生物标志物的开发与验证
本研究评估了Epic Sciences平台检测的循环肿瘤细胞(CTC)数量在转移性去势抵抗性前列腺癌(mCRPC)患者接受雄激素受体信号抑制剂(ARSI)治疗时的预后意义。在MSKCC发现队列(N=171)和PROPHECY验证队列(N=107)中,治疗前CTC计数(以<3 CTCs/mL vs ≥3 CTCs/mL二分)与总生存期(OS)显著相关,发现队列HR=1.8(95%CI 1.3-3.0),验证队列OS HR=1.8(95%CI 1.1-3.0)、无进展生存期(PFS)HR=1.7(95%CI 1.1-2.9),且与CellSearch平台检测结果强相关(r=0.84)。
要点
- 治疗前Epic Sciences平台CTC计数可预测mCRPC患者接受ARSI的OS和PFS。
- CTC计数≥3 CTCs/mL与较差生存显著相关,发现与验证队列HR一致。
- Epic与CellSearch平台CTC计数高度相关(r=0.84)。
核心结论
- 治疗前Epic Sciences平台检测的CTC数量是mCRPC患者起始ARSI治疗时OS的独立预后因素,并在独立队列中验证。
研究设计与样本
- 研究纳入MSKCC发现队列171例和PROPHECY验证队列107例进展性mCRPC患者,治疗前采集血样,使用Epic Sciences平台计数CTC,并与生存关联。
主要发现
- 在MSKCC发现队列中,CTC计数(<3 CTCs/mL vs ≥3 CTCs/mL)是OS的显著预后因素,HR=1.8(95%CI 1.3-3.0)。
- 在PROPHECY验证队列中,CTC计数与OS相关(HR=1.8,95%CI 1.1-3.0)和PFS相关(HR=1.7,95%CI 1.1-2.9)。
- Epic Sciences与CellSearch平台在匹配样本中的CTC计数强相关(r=0.84)。
关键数值与推荐
- CTC计数阈值采用<3 CTCs/mL vs ≥3 CTCs/mL进行二分类分析。
- 多变量分析调整了治疗线数、内脏转移、前列腺特异性抗原、乳酸脱氢酶和碱性磷酸酶。
临床怎么用
- Epic Sciences平台CTC计数可作为mCRPC患者接受ARSI治疗前的预后评估工具,帮助风险分层。
局限性
- 研究为观察性队列,需要前瞻性研究进一步确认CTC计数指导治疗的临床效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the prognostic significance of circulating tumour cell (CTC) number determined on the Epic Sciences platform in men with metastatic castration-resistant prostate cancer (mCRPC) treated with an androgen receptor signalling inhibitor (ARSI). PATIENTS AND METHODS: A pre-treatment blood sample was collected from men with progressing mCRPC starting either abiraterone or enzalutamide as a first-, second- or third-line systemic therapy at Memorial Sloan Kettering Cancer Center (Discovery cohort, N = 171) or as a first- or second-line therapy as part of the multicenter PROPHECY trial (NCT02269982) (Validation cohort, N = 107). The measured CTC number was then associated with overall survival (OS) in the Discovery cohort, and progression-free survival (PFS) and OS in the Validation cohort. CTC enumeration was also performed on a concurrently obtained blood sample using the CellSearch® Circulating Tumor Cell Kit. RESULTS: In the MSKCC Discovery cohort, CTC count was a statistically significant prognostic factor of OS as a dichotomous (<3 CTCs/mL versus ≥ 3 CTCs/mL; hazard ratio [HR] = 1.8 [95% confidence interval {CI} 1.3-3.0]) and a continuous variable when adjusting for line of therapy, presence of visceral metastases, prostate-specific antigen, lactate dehydrogenase and alkaline phosphatase. The findings were validated in an independent datas et from PROPHECY (HR [95% CI] = 1.8 [1.1-3.0] for OS and 1.7 [1.1-2.9] for PFS). A strong correlation was also observed between CTC counts determined in matched samples on the CellSearch® and Epic platforms (r = 0.84). CONCLUSION: The findings validate the prognostic significance of pretreatment CTC number determined on the Epic Sciences platform for predicting OS in men with progressing mCRPC starting an ARSI.
引用
- Scher HI, Armstrong AJ, Schonhoft JD, et al. Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2021. PMID: 33894633. doi:10.1016/j.ejca.2021.02.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。